An interventional study of Complex decongestive therapy and Radial extracorporeal shock wave therapy in Breast Cancer Lymphedema, sponsored by Selcuk University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Selcuk University · Not applicable, Interventional, and Treatment
Arm swelling can persist after breast cancer treatment and may interfere with comfort, movement, and everyday activities. Decongestive care combines several approaches to manage this swelling. This study examined whether adding radial shock wave treatment changed short-term outcomes compared with decongestive care alone.
Twenty-one adults with stage 2 or stage 3 lymphedema affecting one arm were assigned to two treatment groups. Both groups were allocated to a four-week decongestive program. The combined-treatment schedule also included twelve shock wave sessions. Assessments before and after treatment covered arm size, the thickness of the skin and the tissue beneath it, pain, difficulty using the arm, lymphedema-related quality of life, and shoulder and wrist movement. A physician who did not know the treatment assignment performed the physical and ultrasound measurements.
This single-center study evaluated a noninvasive addition to intensive rehabilitation for unilateral upper-limb lymphedema following breast cancer treatment. It was conducted at the Physical Medicine and Rehabilitation Clinic of Selcuk University Faculty of Medicine Hospital in Konya, Türkiye.
The comparison was designed to examine the contribution of radial shock wave treatment separately from the decongestive program received by both groups. Overall limb measurements and regional ultrasound assessments were used to examine different aspects of the response to treatment. Questionnaires and joint measurements provided complementary information about symptoms, everyday arm use, and mobility.
The assessment schedule included examinations before treatment and at the end of the four-week course. Circumference measurements were also obtained weekly during the intervention period. The same physician performed the objective assessments without knowledge of group assignment. Participants and the personnel providing treatment were aware of the assigned intervention.
The Selcuk University Faculty of Medicine Local Ethics Committee approved the study on October 4, 2022, under decision number 2022/410. Each participant provided written consent. This record describes a study that had already been completed before its initial submission to ClinicalTrials.gov.
151 studies on the registry are indexed under Breast Cancer Lymphedema; 45 are open to participants now.
This study's enrollment of 21 is below the median of 51 across 120 interventional studies indexed under Breast Cancer Lymphedema.
Browse Breast Cancer Lymphedema studies →Selcuk University is the lead sponsor of 255 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants were allocated to a four-week course of complex decongestive therapy with additional radial extracorporeal shock wave treatment. Decongestive sessions were scheduled on five days each week, and shock wave sessions on three days each week.
Other: Complex decongestive therapy · Device: Radial extracorporeal shock wave therapy
Participants were allocated to the same four-week complex decongestive program, without shock wave treatment. The planned schedule consisted of five treatment days per week.
Other: Complex decongestive therapy
The planned course comprised four weeks of treatment on five days per week. Components included manual lymphatic drainage, multilayer short-stretch bandaging, skin care, and therapeutic exercise. Exercise activities addressed breathing, posture, shoulder-girdle movement, gentle stretching, and low-intensity active movement of the upper limb and fingers. Movements were performed slowly within a pain-free range while the compression bandages were in place.
An Intelect RPW Lite system (Chattanooga) was used to deliver radial pressure pulses with the participant lying supine. The scheduled regimen consisted of three sessions per week for four weeks. Each session used a pressure setting of 2 bar and a frequency of 4 Hz, with 2,500 pulses in total. Of these, 750 were directed to the axillary region and 250 to the cubital region; the remaining 1,500 were distributed across the arm, forearm, and hand.
Reduction in calculated affected upper-limb volume
Volume of the affected upper limb was estimated from circumference measurements using the truncated-cone method and expressed in liters. The week-4 volume was subtracted from the pretreatment volume. A positive value indicates a reduction in calculated limb volume.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in arm circumference 10 cm above the cubital fossa
Circumference of the affected arm was measured in centimeters at a level 10 cm proximal to the cubital fossa. The reduction was calculated as the pretreatment measurement minus the week-4 measurement. Positive values represent a smaller circumference after treatment.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in forearm circumference 10 cm below the cubital fossa
Circumference of the affected forearm was recorded in centimeters at a level 10 cm distal to the cubital fossa. The week-4 measurement was subtracted from the pretreatment measurement. Positive values represent a decrease in circumference.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in skin thickness at 10 cm proximal to the cubital fossa
The thickness of the skin in the affected upper limb was measured 10 cm proximal to the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in skin thickness at the cubital fossa
The thickness of the skin in the affected upper limb was measured at the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in skin thickness at 10 cm distal to the cubital fossa
The thickness of the skin in the affected upper limb was measured 10 cm distal to the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in subcutaneous tissue thickness at 10 cm proximal to the cubital fossa
The thickness of the subcutaneous tissue in the affected upper limb was measured 10 cm proximal to the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in subcutaneous tissue thickness at the cubital fossa
The thickness of the subcutaneous tissue in the affected upper limb was measured at the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in subcutaneous tissue thickness at 10 cm distal to the cubital fossa
The thickness of the subcutaneous tissue in the affected upper limb was measured 10 cm distal to the cubital fossa by ultrasound using a linear-array transducer. Values were recorded in millimeters by the masked physician. Reduction was calculated as pretreatment thickness minus week-4 thickness; a positive value denotes thinning of the measured layer.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score
The Turkish QuickDASH questionnaire was used to assess upper-limb symptoms and activity limitations. This 11-item instrument produces a score from 0 to 100, with higher values indicating greater disability. The reduction was calculated as the baseline score minus the week-4 score; a positive value indicates improvement.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in upper-limb pain on the Visual Analog Scale
Participants rated pain in the affected upper limb using a Visual Analog Scale scored from 0, indicating no pain, to 10, indicating the most severe pain. Pain reduction was calculated by subtracting the week-4 score from the pretreatment score. Positive values indicate lower pain after treatment.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in the Lymphedema Quality of Life Questionnaire-Arm function domain score
The function domain of the Turkish Lymphedema Quality of Life Questionnaire-Arm assessed limitations in daily activities attributable to arm lymphedema. Domain scores range from 1 to 4, with higher scores indicating greater impairment. The baseline domain score minus the week-4 domain score was calculated; positive values indicate improvement.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in the Lymphedema Quality of Life Questionnaire-Arm appearance domain score
The appearance domain of the Turkish Lymphedema Quality of Life Questionnaire-Arm assessed the perceived effect of arm lymphedema on appearance. Domain scores range from 1 to 4, with higher scores indicating greater impairment. The baseline domain score minus the week-4 domain score was calculated; positive values indicate improvement.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in the Lymphedema Quality of Life Questionnaire-Arm symptoms domain score
The symptoms domain of the Turkish Lymphedema Quality of Life Questionnaire-Arm assessed symptoms associated with arm lymphedema. Domain scores range from 1 to 4, with higher scores indicating greater impairment. The baseline domain score minus the week-4 domain score was calculated; positive values indicate improvement.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Reduction in the Lymphedema Quality of Life Questionnaire-Arm mood domain score
The mood domain of the Turkish Lymphedema Quality of Life Questionnaire-Arm assessed the emotional impact of arm lymphedema. Domain scores range from 1 to 4, with higher scores indicating greater impairment. The baseline domain score minus the week-4 domain score was calculated; positive values indicate improvement.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Increase in active shoulder flexion, abduction, adduction, extension, external rotation, internal rotation
Active shoulder flexion, abduction, adduction, extension, external rotation,internal rotation of the affected shoulder were measured in degrees with a standard goniometer by the masked physician. The pretreatment value was subtracted from the week-4 value. A positive result indicates an increase in the available range of motion.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Increase in active wrist flexion, extension, radial deviation, ulnar deviation
Active flexion, extension, radial deviation,ulnar deviation of the affected wrist were measured in degrees with a standard goniometer by the masked physician. Changes were calculated as the week-4 value minus the pretreatment value. Positive values indicate a gain in range of motion.
Time frame: Before the first treatment session and at the end of the four-week treatment course.
Plan to share: Yes — De-identified participant-level data supporting the published findings will be made available to researchers following approval of a reasonable request submitted to the corresponding author. Requests will be assessed by the study team. Any data transfer will be subject to applicable institutional and ethical requirements and must be consistent with participant consent and the protection of participant confidentiality.
Access criteria: Researchers should contact the corresponding author and explain the purpose of the request and the intended use of the data. Access will be granted following review and approval by the study team, subject to ethical and institutional requirements.
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Apr 2024, 17 months.
Of 78 non-industry interventional studies with no phase under Breast Cancer Lymphedema, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 71. This study's 17 months is below that.
Counting every sponsor, half of 81 studies reached it within 18 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.